Information on K/NRAS and BRAF mutations was less complete than information on MSI status, as analysis of MSI status is regarded as essential for all newly diagnosed patients with CRC, while the analysis of K/NRAS and BRAF mutations is made upon request, serving to individualize the oncological treatment course. The gene discussed is NRAS; the disease is colorectal carcinoma.